Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Chief Scientific Officer | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Werewolf Therapeutics, Inc.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2033-12-31 | Direct | 150,000 |
Reported balance
After 2024-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 150,000 · Balance 150,000 F1: The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 4, 2024 21:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0000950170-24-001907 · ownership.xml · derivative · entry 1 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028. Read SEC document |
| January 03, 2023 Filed Jan 10, 2023 02:36 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 115,900 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0000899243-23-001409 · doc4.xml · derivative · entry 1 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,900 Underlying: Common Stock · 115,900 shares Expires 2032-12-31 F1 · derivative.exercise_date: The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:58 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | Exercise / conversionStock Option (right to buy) · Derivative | 15,532 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0000899243-22-002027 · doc4.xml · derivative · entry 5 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,631 Underlying: Common Stock · 15,532 shares Expires 2030-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:58 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | Exercise / conversionStock Option (right to buy) · Derivative | 24,199 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000899243-22-002027 · doc4.xml · derivative · entry 4 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,937 Underlying: Common Stock · 24,199 shares Expires 2030-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on May 20, 2020 with a Vesting Commencement Date of June 1, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through June 1, 2024. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:58 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | Exercise / conversionCommon Stock | 15,532 | $4.77 | $74,087.64 |
DisclosureSEC source: 0000899243-22-002027 · doc4.xml · nonDerivative · entry 2 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:58 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | Exercise / conversionCommon Stock | 24,199 | $1.56 | $37,750.44 |
DisclosureSEC source: 0000899243-22-002027 · doc4.xml · nonDerivative · entry 1 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 14, 2022 22:58 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 79,516 | $0.00 Strike: $11.55 | $0.00 |
DisclosureSEC source: 0000899243-22-002027 · doc4.xml · derivative · entry 3 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,516 Underlying: Common Stock · 79,516 shares Expires 2032-01-05 F1 · derivative.exercise_date: The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026. Read SEC document |
| April 30, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 57,908 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018112 · doc4.xml · derivative · entry 2 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,908 Underlying: Common Stock · 57,908 shares Expires 2031-04-29 F2 · derivative.exercise_date: The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025. Read SEC document |
| December 08, 2020 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 99,163 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0000899243-21-018112 · doc4.xml · derivative · entry 1 Seidel-Dugan Cynthia · CIK 0001857799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,163 Underlying: Common Stock · 99,163 shares Expires 2030-12-07 F1 · derivative.exercise_date: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.